Drug Discovery World

JANUARY 2, 2024

More significantly, she says, with the boost from what we have learned from Covid, cancer vaccines will become a reality. She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer.

Research 148

Research Vaccine Science Trials 148

Drug Discovery World

APRIL 10, 2023

India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. India’s domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 2. Hyderabad is recognised as the vaccine hub of India.

Vaccine 130

Vaccine Pharmaceuticals Drugs Science 130

Drug Discovery World

OCTOBER 6, 2022

until 2030. In Germany the development of the Covid-19 vaccine, largely due to the achievements of BioNTech, raised the country’s biotech profile. Lang notes: “The opportunities extend beyond coronavirus vaccines. Lu Rahman highlights some of the key players. . The European drug discovery sector is buoyant. Valued at $14.8

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

The Pharma Data

JUNE 26, 2021

Sanofi Aims for Carbon Neutrality Sanofi has committed to reduce its greenhouse gas emissions by 55% by 2030 in line with limiting global warming to 1.5°C C and is aiming for carbon neutrality by 2050. More on Sanofi’s environmental management and achievements: [link].

Packaging 52

Packaging Vaccine Production Science 52

The Pharma Data

APRIL 7, 2021

In this context, Sanofi, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. Zero plastic packaging for vaccines and ecodesign of products.

Packaging 52

Packaging Vaccine Disease Treatment 52

The Pharma Data

NOVEMBER 16, 2020

WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Meeting the following targets by 2030 will place all countries on the path toward elimination: 90% of girls fully vaccinated with the HPV vaccine by 15 years of age.

Vaccine 40

Vaccine Treatment Disease Engineering 40

The Pharma Data

APRIL 22, 2023

Since 1997, WHO and UNICEF have jointly collected information on immunization programmes and vaccine-preventable diseases. In 2020, WHO Member States endorsed the Immunization Agenda 2030 (IA2030), where eJRF data is used to report on the monitoring and evaluation framework that guides immunization strategies at global and regional levels.

Vaccine 40

Vaccine Disease 40

The Pharma Data

SEPTEMBER 30, 2021

Today on World Rabies Day, we commemorate the death of Pasteur who developed the primary rabies vaccine, laying the foundations for rabies prevention. The COVID-19 pandemic has resulted in an upsurge of anti-vax and anti-science movements, yet vaccination and awareness can save lives.

Vaccine 52

Vaccine Government Disease International 52

The Pharma Data

NOVEMBER 5, 2020

For the first time, the world has rallied behind a plan to accelerate the development of the vaccines, diagnostics and therapeutics we need, and to ensure they are available to all countries on the basis of equity. The Access to COVID-19 Tools (ACT) Accelerator is delivering real results.

International 52

International Compliance Virus Vaccine 52

The Pharma Data

NOVEMBER 16, 2020

HPV vaccination, screening and treatment for cervical pre-cancer and cancer, which are critical to preventing and managing cervical cancer are yet to be fully scaled up, contributing. care by 2030. care by 2030. choice and improving access to vaccination for girls and screening and treatment for women is critical.

Vaccine 52

Vaccine Treatment Virus 52

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. Everyone enjoys a good news story and the drug discovery and development sector is no exception. References .

Drugs 130

Drugs Engineering Clinical Trials Science 130

The Pharma Data

DECEMBER 1, 2020

Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 was endorsed by the Seventy-third World Health Assembly last week. She said achieving the 2030 goals will happen only with collaboration and coordination across sectors, with strong country ownership.

Vaccine 52

Vaccine Disease Government Science 52

The Pharma Data

MAY 5, 2022

Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines. Vanina Laurent-Ledru will lead Foundation S.

Vaccine 52

Vaccine Hospitals International Treatment 52

The Pharma Data

OCTOBER 28, 2021

billion (up 10.1%) due to strong growth from Dupixent ® , Vaccines and CHC. Vaccines up16.5, with record daily deals driven by discerned flu vaccines and meningitis ballot recovery. We help illness with vaccines, give innovative treatments to fight pain and ease suffering. Q3 2021 sales grew double digit to €10.4

Vaccine 52

Vaccine Treatment Drugs 52

Drug Discovery World

APRIL 12, 2023

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. Dr Paul Burton, the Chief Medical Officer of Moderna, told the Guardian: “We will have that vaccine and it will be highly effective, and it will save many hundreds of thousands, if not millions of lives.

Vaccine 130

Vaccine Immune Response RNA DNA 130

The Pharma Data

NOVEMBER 11, 2021

By 2030, we aim to impact the lives and health of 50 million people and engage 20,000 Boehringer Ingelheim employees, through supporting social entrepreneurs in vulnerable communities.”. Today marks the inaugural start of the “Making More Health Together 2021″ convention.

Vaccine 40

Vaccine Therapies Marketing Research 40

The Pharma Data

MARCH 23, 2023

The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Therapies 40

Therapies Treatment Vaccine Production 40

NIH Director's Blog: Drug Development

MAY 15, 2018

So, researchers have been searching the genome of Plasmodium falciparum , the most-lethal species of the malaria parasite, for potentially better targets for drug or vaccine development. That list of 2,680 essential genes now becomes an important starting point for future research as well as drug and vaccine development.

Drug Development 52

Drug Development Drugs Disease Vaccine 52

Drug Discovery World

APRIL 25, 2024

billion in 2022, a figure that is expected to grow at a compound annual growth rate (CAGR) of 9.81% from 2023 to 2030 1. One of the most recent drivers of the cell line development market came from the Covid-19 pandemic, where research into vaccines skyrocketed and demand for cell lines was boosted as a result.

Vaccine 148

Vaccine Production Pharmaceuticals Therapies 148

Drug Discovery World

AUGUST 8, 2023

In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1. DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest.

Research 130

Research Pharmacy Pharmaceuticals Government 130

Drug Discovery World

MAY 7, 2024

It was founded in 2020 to connect industry, academia and the NHS and help discover and develop new treatments, including diagnostics, vaccines and preventative products for infective diseases. iiCON specifically is a major advocate for work tackling AMR. If that works, we should be taking that into a large-scale population Phase III trial.”

Vaccine 148

Vaccine Pharmaceutical Companies Clinical Trials Trials 148

The Pharma Data

MAY 4, 2021

” “Even as the world makes progress on vaccine roll-outs, it remains vital for treatments to be available that can make a meaningful difference for those fighting COVID-19,” said David A. Ricks , Lilly chairman and CEO. It was identified from a blood sample taken from one of the first U.S.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Drug Discovery World

JUNE 26, 2023

Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global pandemic for it to become a reality. Now, there are many mRNA-based therapeutics in clinical development and mRNA cancer vaccines have been promised by 2030.

Vaccine 130

Vaccine Virus Clinical Trials Trials 130

The Pharma Data

JANUARY 9, 2021

• Anthrax Vaccines. Anthrax vaccine revenues are expected to be at a more normalized annual level and continue to primarily reflect procurement of AV7909 (Anthrax Vaccine Adsorbed, adjuvanted) under the Company’s existing contract with the Biomedical Advanced Research and Development Authority (BARDA).

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

DECEMBER 18, 2020

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

Vaccine 52

Vaccine Government International Virus 52

Drug Discovery World

JANUARY 19, 2023

pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines. billion by 2030 (BioSpace, 11 August 2022). This rapid emergence of cell and gene therapies has fuelled demand for plasmids and has created a manufacturing ‘bottleneck’.

DNA 130

DNA Therapies Assay Development Production 130

Drug Discovery World

FEBRUARY 15, 2023

Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets). Rising demand The global immuno-oncology assay market is expected to grow at a compound annual growth rate (CAGR) of 11.87% from 2021 to 2030 to reach 11.74bn USD by 2030 7.

Research 130

Research Therapies Immune Response Clinical Trials 130

Drug Discovery World

MAY 30, 2023

Very recent data from Moderna’s and BioNTech’s personalised vaccines in combination with ICIs in melanoma and pancreatic cancer respectively have shown dramatic improvements when given as part of a triple combination (vaccine plus ICI and chemo/radiotherapy).

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. MenAfriVac is a meningococcal vaccine that remains active, without refrigeration, for up to four days and has significantly boosted vaccine coverage in parts of sub-Saharan Africa. We further estimate that supplying just the U.S.

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Disease Vaccine Licensing 52

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

PerkinElmer

JANUARY 25, 2023

There is a strong will to increasing the number of newborns screened for sickle cell disease (SCD) from its current level of 4% to 50% by 2030. Big, bold commitments such as these will hopefully continue in the year ahead. Furthermore, technological improvements will be a driving force behind future advances in NBS globally.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. Polio/Pertussis/Hib vaccines (incl. Influenza vaccines (incl. Meningitis/Pneumo vaccines (incl.

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. Speeding up sales growth. Sales growth at Bayer is planned to regain momentum in 2021 and further accelerate in the years thereafter.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030. Nat Rev Dis Primers.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

Codon

MARCH 3, 2024

Link Making Pan-Vaccines Current vaccines typically offer narrow protection against pathogens, such as influenza. As pathogens evolve and mutate, though, they can find ways to evade that protection, thus requiring that people get vaccinated repeatedly. Link Quadrivalent Influenza Vaccine. per kilo by 2030.

DNA 89

DNA Engineering Vaccine Virus 89